Topical mupirocin was routinely applied to insertion sites of central venous catheters (CVC) of neonates in a neonatal intensive care unit. After five years, mupirocin resistance was recorded in 42% of clinical isolates of coagulase-negative staphylococci (CNS). This decreased to 21% during a mupirocin-free interval of five months. We performed a prospective study on the significance of mupirocin use on the staphylococcal skin flora of 15 newly admitted neonates. During treatment, mupirocin-susceptible strains were replaced by highly resistant ones. After treatment, all but one neonate harboured at least one resistant strain; 29% of all strains were moderately resistant (mupirocin minimum inhibitory concentrations (MICs) 16mg/L) and 55% were highly resistant (MICs >1024mg/L). One CVC (7%) became colonized with a resistant strain, One year after stopping routine mupirocin application the incidence of resistance had dropped to 13%; CVC colonization was recorded in 2*4%.
and th en one m onth after réintrodu ction o f the antibiotic. C ontrols were isolates from 36 patients h osp italized in an I C U w ard w here m upirocin had never been used. S u bseq uen tly, the in flu en ce o f m upirocin on C N S from skin flora was studied p ro sp ectiv ely in 15, n ew ly adm itted, consecutive neonates (age 2 -3 6 days), all w ith C V C s in situ . M u p irocin ointm ent (2% g/g) was applied once daily to the C V C in sertion site for 2 -2 4 days (mean seven days). One skin swab was taken from each insertion site and the opposite site of the b od y before and d u ring the in sertion period (day 3-7) and after rem oval of the C V C (seven and 14 days after). Sam ples were cultured on 5% blood agar and m a n n ito l-sa lt agar (48 h at 35°C, 5% C 0 2) and in Iso-sen sitest broth, w h ich w as su b cu ltu red after overnight incubation at 35°C on to blood agar and m a n n ito l-sa lt agar. 
R esults M u p irocin resistance w as fou n d in clinical isolates o f five out of nine patients in the N I C U during D ecem b er 1991. A t th e end of a five-m onth m u p irocin -free period (from 1 M ay 1992-1 O ctob er 1992) the resistance rate w as 21%, com pared w ith 8% in patients in the m upirocin-free IC U w here m u p irocin was never used (P -0 *2). R éin trod u ction of m upirocin into the N I C U resulted in an in-vitro resistance rate of 42% am ong clin ical isolates after on e m onth (N ovem ber 1992), w hereas the prevalence in the com parative IC U was 5% (P<0-05) (T able I).
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sa p ro p h y tic u s (1%). T h e su scep tib ility o f these C N S to m upirocin is sh ow n in T ab le II. Initially seven patients had only susceptible strains, three had both su scep tib le and low -resistan t strains and five harboured b oth su scep tib le and h ig h ly resistant strains. T h e num ber o f resistant strains increased during treatm ent: on days 3-7, seven of 13 neonates had
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